(Reuters) -Roche Group said on Monday that it plans to invest more than $700 million in a new drug manufacturing facility in North Carolina, the latest drugmaker to expand its presence in the United States amid President Donald Trump’s tariff policies.
The new facility, based in Holly Springs, North Carolina, will support Roche and its unit Genentech’s future portfolio of next-generation obesity medicines.
Separately, Roche also announced plans to invest up to $550 million in its diagnostics site in Indianapolis by 2030, to manufacture continuous glucose monitoring systems.
Roche acquired rights to petrelintide, an obesity therapy from Denmark’s Zealand Pharma in March. This therapy is currently undergoing mid-stage clinical trials.
Roche’s obesity pipeline also includes experimental obesity and diabetes drugs from its acquisition of Carmot Therapeutics in 2023.
“This initial investment could expand in the future, based on business needs and the U.S. policy environment,” the company said in a statement.
Roche in April said it would invest $50 billion in the United States over the next five years, with plans to create more than 12,000 new jobs.
This announcement is part of a broader trend of massive investments by drugmakers such as Eli Lilly, Johnson & Johnson and Gilead that have also recently pledged additional investments to boost domestic production in response to President Trump’s tariff policies.
The Trump administration has been pressuring U.S. drugmakers to relocate production domestically. Last week, President Trump signed an executive order to expedite pharmaceutical plant approvals, encouraging U.S.-based manufacturing.
Trump also said he plans to sign an executive order on prescription drug pricing on Monday that aims to align the United States with what other countries pay, a move he said on social media could result in a 59% reduction in drug prices.
(Reporting by Sneha S K in Bengaluru; Editing by Tasim Zahid and Shailesh Kuber)
